University of California San Francisco

Nola Hylton, PhD

Nola Hylton, PhD
Nola Hylton, PhD

Professor, School of Medicine, Radiology

Address

550 16th Street
San Francisco, CA 94158
United States

Email: [email protected]

ORCID: 0000-0002-6747-1662

Awards & Honors

Award Conferred By Date
Distinguished Investigator Academy of Radiology Research 2013
Cure Scholar Award Komen 2010
Scientific Advisory Council Susan G. Komen for the Cure's 2010
Research Scholar American Cancer Society 2003
Outstanding Contribution Award American College of Radiology Imaging Network 2003
Editor's Recognition Award with Distinction Radiology 1987/1988
Graduate Professional Opportunities Program Fellowship Stanford University 1979
Undergraduate Fellowship Bell Telephone Laboratories 1975

Clinical Trials

  1. Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS) (NCT00804128)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  2. DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy (NCT01564368)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  3. Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ (NCT00290745)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  4. Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer (NCT00043017)
    Related Conditions: Breast Cancer, MRI, Neuroimaging| Start Date: | End Date:

Grants and Funding

  • Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials | NIH | 2008-04-25 - 2021-06-30 | Role: Principal Investigator
  • Quantitative Imaging for Assessing Breast Cancer Response to Treatment | NIH | 2011-09-26 - 2016-08-31 | Role: Principal Investigator
  • MRI For Staging DCIS and Assessing Response to Treatment | NIH | 2006-08-23 - 2013-07-31 | Role: Principal Investigator
  • NMR Imaging and Spectroscopy | NIH | 1993-06-01 - 2013-05-31 | Role: Co-Investigator
  • Anatomic and Biologic Staging of Breast Disease with MRI | NIH | 1997-01-15 - 2012-02-28 | Role: Principal Investigator
  • Mechanism-Based Evaluations of ErbB-Targeted Agents | NIH | 2001-09-26 - 2008-12-31 | Role: Co-Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. The Future of Quantitative Breast Imaging: Integrated to Integral Imaging Biomarkers for Precision Cancer Care, From the AJR Special Series on Quantitative Imaging.
    McDonald ES, Kazerouni AS, Metanet P, Barinov L, Partridge SC, Hylton NM| | PubMed
  2. A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.
    Switalla KM, Onishi N, Jones EF, Lawhn-Heath C, Ray KM, Hathi DK, Carmona-Bozo JC, Metanat P, Lopes AJ, Falade IO, Quirarte A, Gottipati S, Guo R, Molina-Vega J, Pullakhandam K, Bareng TJ, Watkins M, Chien AJ, Joe BN, Esserman LJ, Hylton N, Mukhtar RA| | PubMed
  3. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue.
    Goldhammer N, Bont M, Warhadpande S, Choi M, Cedano J, Greenwood H, Ye J, Schwartz CJ, Alvarado M, Ewing C, Goodwin K, Mukhtar RA, Wong J, Abe SE, Chandler J, Jackson J, Olopade OI, Campbell MJ, Lam A, Park C, Vertido A, van 't Veer LJ, Hylton N, Esserman LJ, Rosenbluth JM| | PubMed
  4. Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.
    Basu A, Umashankar S, Melisko M, Roy R, Yau C, Pusztai L, Chien AJ, Liu M, Han H, Soliman H, Isaacs C, Shatsky R, Stringer-Reasor E, Robinson P, Yeung K, Kalinsky K, Thomas A, Philip E, Musthafa M, Hirst G, Asare A, DeMichele A, Van't Veer L, Yee D, Hylton N, Olshen A, Perlmutter J, Cohen RN, Quandt Z, Esserman L, Hershman D, Rugo H, Nanda R| | PubMed
  5. RISE UP for breast cancer 2024: conference highlights & takeaways.
    Glatt T, Leggat-Barr K, Seth N, Heditsian D, van 't Veer L, Pusztai L, Price E, Hylton N, Formenti S, Rugo H, Fejerman L, Toriola AT, Fabian C, De Censi A, Grossman D, Olopade O, Jackson A, Horton S, Rhoads K, Lange C, Borges V, Garner E, Garber J, Yee D, Esserman L| | PubMed
  6. CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
    Wahner Hendrickson AE, Flatten KS, Weiskittel TM, Venkatachalam A, Strathman AR, Rossman OK, Meng XW, Schneider PA, Peterson KL, Correia C, Anderson OJ, Singh S, Couch FJ, Esserman LJ, Hylton NM, Onishi N, DeMichele AM, Chen J, Li H, Ingle JN, Goetz MP, Kaufmann SH| | PubMed
  7. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
    Van Hassel J, Dimitroff K, Yau C, Mukhtar R, Boughey JC, Ladores V, Howard-McNatt MM, Jaskowiak N, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Veer LV, Rugo H, Esserman LJ, Shatsky R, Isaacs C, Kuerer H, Wallace AM, Prionas N, Tseng J, Reyna CR, Taunk N, Kesmodel S, Lee MC, Fox J, Piltin MA, Tchou J, Arciero CA, Postlewait LM, Sauder C, Rao R| | PubMed
  8. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
    Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, Van't Veer L, Boughey JC| | PubMed
  9. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
    Kaur M, Dimitroff K, Boughey JC, Esserman LJ, Yau C, Tchou J, Quirarte A, Lee MC, Howard-McNatt MM, Switalla K, Kuerer H, Sauder C, Postlewait LM, Arciero C, Rao R, Wallace A, Reyna C, Ahmed K, Gutnik L, Taunk N, Perlmutter J, DeMichele A, Yee D, Hylton NM, Symmans WF, Rugo HS, Shatsky RA, Isaacs C, Rudra S, Pohlmann P, Ewing C, Wong J, Alvarado M, Jaskowiak N, Prionas N, Golshan M, Piltin MA, Olopade OI, Mukhtar RA| | PubMed
  10. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Leon-Ferre RA, Dimitroff K, Yau C, Giridhar KV, Mukhtar R, Hirst G, Hylton N, Perlmutter J, DeMichele A, Yee D, van 't Veer L, Rugo H, Symmans WF, Goetz MP, Esserman L, Boughey JC| | PubMed